title: Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.
abstract: BACKGROUND
  The Brugada syndrome is an arrhythmogenic disease caused in part by mutations in the cardiac sodium channel gene, SCN5A. The electrocardiographic pattern characteristic of the syndrome is dynamic and is often absent in affected individuals. Sodium channel blockers are effective in unmasking carriers of the disease. However, the value of the test remains controversial.
  
  
  RESULTS
  We studied 147 individuals representing 4 large families with SCN5A mutations. Of these, 104 were determined to be at possible risk for Brugada syndrome and underwent both electrocardiographic and genetic evaluation. Twenty-four individuals displayed an ECG diagnostic of Brugada syndrome at baseline. Of the remaining, 71 received intravenous ajmaline. Of the 35 genetic carriers who received ajmaline, 28 had a positive test and 7 a negative ajmaline test. The sensitivity, specificity, and positive and negative predictive values of the drug challenge were 80% (28:35), 94.4% (34:36), 93.3% (28:30), and 82.9% (34:41), respectively. Penetrance of the disease phenotype increased from 32.7% to 78.6% with the use of sodium channel blockers. In the absence of ST-segment elevation under baseline conditions, a prolonged P-R interval, but not incomplete right bundle-branch block or early repolarization patterns, indicates a high probability of an SCN5A mutation carrier.
  
  
  CONCLUSIONS
  In families with Brugada syndrome, the data suggest that ajmaline testing is valuable in the diagnosis of SCN5A carriers. In the absence of ST-segment elevation at baseline, family members with first-degree atrioventricular block should be suspected of carrying the mutation. An ajmaline test is often the key to making the proper diagnosis in these patients.
authors.affiliation: Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501, USA.
authors.forename: Kui
authors.initials: K
authors.lastname: Hong
authors.forename: Josep
authors.initials: J
authors.lastname: Brugada
authors.forename: Antonio
authors.initials: A
authors.lastname: Oliva
authors.forename: Antonio
authors.initials: A
authors.lastname: Berruezo-Sanchez
authors.forename: Domenico
authors.initials: D
authors.lastname: Potenza
authors.forename: Guido D
authors.initials: GD
authors.lastname: Pollevick
authors.forename: Alejandra
authors.initials: A
authors.lastname: Guerchicoff
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Matsuo
authors.forename: Elena
authors.initials: E
authors.lastname: Burashnikov
authors.forename: Robert
authors.initials: R
authors.lastname: Dumaine
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Towbin
authors.forename: Vladislav
authors.initials: V
authors.lastname: Nesterenko
authors.forename: Pedro
authors.initials: P
authors.lastname: Brugada
authors.forename: Charles
authors.initials: C
authors.lastname: Antzelevitch
authors.forename: Ramon
authors.initials: R
authors.lastname: Brugada
mesh_terms: D000404:Ajmaline; D004562:Electrocardiography; D005260:Female; D005820:Genetic Testing; D006327:Heart Block / Q000175:diagnosis / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D008297:Male; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010375:Pedigree; D012306:Risk; D012680:Sensitivity and Specificity; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000172:deficiency* / Q000235:genetics; D013577:Syndrome; D017180:Tachycardia, Ventricular / Q000175:diagnosis* / Q000235:genetics
chemical_list: D062554:NAV1.5 Voltage-Gated Sodium Channel; C568320:SCN5A protein, human; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D000404:Ajmaline